MedTrace Logo

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2024-09-19

No results posted yet for this study

Summary

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Conditions

  • Advanced Solid Tumor
  • Homologous Recombination Deficiency
  • HRR Deficiency

Interventions

DRUG

EIS-12656

EIS-12656 tablets given daily

DRUG

Olaparib

as per USPI/SmPC

DRUG

Trastuzumab deruxtecan

as per USPI/SmPC

Sponsors & Collaborators

  • Eisbach Bio GmbH

    lead INDUSTRY

Principal Investigators

  • Timothy Yap · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2027-09-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06525298 on ClinicalTrials.gov